Feeds:
Posts
Comments

Posts Tagged ‘morgenthaler ventures’

SALE OF CardioMind, INC.

Gerbsman Partners has been retained by CardioMind, Inc. to solicit interest for the acquisition of all, or substantially all, the assets of CardioMind Inc.

IMPORTANT LEGAL NOTICE:

The information in this memorandum does not constitute in whole or in part an offer or a contract.

The information contained in this memorandum relating to CardioMind‘s Assets has been supplied by CardioMind. It has not been independently investigated or verified by Gerbsman Partners or its agents.

Potential purchasers should not rely on any information contained in this memorandum or provided by CardioMind, or Gerbsman Partners (or their respective staff, agents, and attorneys) in connection herewith, whether transmitted orally or in writing as a statement, opinion, or representation of fact. Interested parties should satisfy themselves through independent investigations as they or their legal and financial advisors see fit.

CardioMind, Gerbsman Partners, and their respective staff, agents, and attorneys, (i) disclaim any and all implied warranties concerning the truth, accuracy, and completeness of any information provided in connection herewith and (ii) do not accept liability for the information, including that contained in this memorandum, whether that liability arises by reasons of CardioMind‘ or Gerbsman Partners” negligence or otherwise.

It is expected that any sale of the CardioMind Assets will be made on an “as-is,” “where-is,” and “with all faults” basis, without any warranties, representations, or guarantees, either express or implied, of any kind, nature, or type whatsoever from, or on behalf of CardioMind or Gerbsman Partners. Without limiting the generality of the foregoing, CardioMind and Gerbsman Partners and their respective staff, agents, and attorneys, hereby expressly disclaim any and all implied warranties concerning the condition of the CardioMind Assets and any portions thereof, including, but not limited to, the implied warranties of habitability, merchantability, or fitness for a particular purpose.

This memorandum contains confidential information and is not to be supplied to any person without Gerbsman Partners’ prior consent. This memorandum and the information contained herein are subject to the non-disclosure agreement attached hereto as Exhibit A.

CardioMind, Inc.

Headquartered in Sunnyvale, California, CardioMind, Inc. is a development stage company focused on a unique stent delivery platform that has applications in treating coronary, neuro and peripheral artery disease.

CardioMind believes its assets are attractive for a number of reasons:

1. CardioMind’s Sparrow bare metal stent systems are CE Marked and represent:
– the first stent “in a guidewire” system ever approved for sale.
– the lowest profile (.014 Inch maximum diameter) stent system ever approved for sale.
– the stent with the thinnest struts ever approved for sale.
– the first approved stent system specifically designed to treat vessels below 2.75 mm.

2. CardioMind has data on its Sparrow drug eluting stent out to 8 months that shows binary restenosis rates of 6.7% in vessels whose mean diameter is 2.27 mm with a mean in-lesion late loss of .23 mm. This data was collected from world respected cardiology centers in Europe, Asia, Australia, and South America in a multicenter controlled randomized trial and analyzed by key ivus and angiographic core laboratories. Data sets and data bases available during due diligence process.

3. CardioMind has extensive data from bench, preclinical, and clinical studies that was used to get the CE Mark on the bare metal stent and is in process of using existing data to get the CE mark for its drug eluting stent.

4. CardioMind has existing bare metal inventory that can be used for clinical evaluation and sale preference testing in Europe.

Intellectual Property Summary

At present, CardioMind has 2 issued US patents, 14 pending patent applications of which 2 have been allowed, and 14 pending international patent applications of which 1 has been allowed. These patents and patent applications are in the area of implant and/or stent delivery technology and stent construction technology and describe among other things:

* A low-profile implant/stent delivery device having an implant/stent releasably secured to a delivery guide member.

* Stent delivery systems comprising an elongate stent carrying member that serves as a guidewire for a balloon catheter that can be used, for example, for vessel predilation or postdilation of an emplaced stent. And methods of passing a balloon catheter over an elongate stent carrying member, which serves as a guidewire.

* Prosthesis twist-down delivery systems including a prosthesis mounted on an elongate member in a twisted reduced diameter configuration and stent configurations suitable for twisting.

* Implant/stent holding and release approaches to releasably hold an implant/stent to a delivery guide including mechanical and electrolytic mechanisms.

* Power delivery technology for releasing electrolytically erodable stent holding mechanisms.

CardioMind has allowed claims involving methods for treating a vessel including passing a balloon catheter over an elongate stent carrying member, which serves as a guidewire for the balloon catheter. CardioMind also has allowed claims involving a system comprising prosthesis structure being in a twisted reduced diameter configuration and releasably mounted on an elongate member. These allowed claims also include other language as will be apparent from reviewing the claims. Other aspects of the technology also are being pursued.

Sparrow is a differentiated stent and delivery technology

* The stent “in a guidewire” technology is unique to CARDIOMIND and may offer significant clinical benefits.

* The Sparrow’s low profile and guidewire integration allows for significantly improved delivery and access to distal lesions, lesions in tortuous anatomy, small vessels, lesions distal to previously placed stents, and access through stent struts to treat bifurcations.

* The Sparrow allows direct access to the lesion with the Sparrow being used as the lead guidewire. The Sparrow guidewire can then be used to rail a rapid exchange catheter over its shaft and stent. Alternatively, the Sparrow with its stent attached can fit through any standard .014 inch catheter lumen (infusion or balloon).

Large and well established stent market

* Existing $5 billion worldwide coronary stent market.

* Existing reimbursement.

* Physician base known for rapid adoption of new technologies that provide improved safety/efficacy and/or greater efficiency.

* Neurovascular Stent: The Sparrow can be used in neurovascular anatomy to treat ischemic stroke, atherosclerotic disease, or bridge aneurysms prior to coiling. Existing stents with much stiffer, bulkier delivery systems are priced at $6000 for bare metal stents. There are over 700,000 ischemic strokes in the US annually. Access is a key issue in treatment of distal, tortuous neurovascular disease.

* Peripheral Stent: The Sparrow can access distal parts of the peripheral vascular system to treat unmet clinical needs in erectile dysfunction and distal disease in the leg. The Sparrow system is extremely flexible and trackable and may be able deliver a self-expanding stent to distal, tortuous anatomy better than current systems. These markets represent markets over $500MM.

CardioMind Company Profile

CardioMind was founded in 2003 and raised approximately $53 million through private placements of its convertible preferred stock involving leading venture capital firms including Latterell Venture Partners, Morgenthaler Ventures, InterWest Partners, De Novo Ventures, SV Life Sciences, and Onset Ventures.

CardioMind is a developer of the innovative “stent in a guidewire” Sparrow system using both drug eluting and bare metal stent systems for the treatment of coronary artery disease, neurovascular disease and peripheral vasculature disease. The CardioMind® Sparrow Stent is the only stent system designed specifically to treat small vessel disease and offers delivery on a guidewire that has a profile 70% smaller than any commercial competitor.

CardioMind’s stent systems are the only stent systems designed to enable physicians to access lesions with combination wire/stent that acts as a lead wire. CardioMind’s stent systems are designed to treat small vessels and distal, hard to reach anatomy in coronary, neuro and peripheral vasculature.

Impact of Technology on the Market

CardioMind believes that its “stent in a guidewire” technology offers advantages over currently marketed stents.

* The “stent in a guidewire” technology is unique to CARDIOMIND and may offer significant clinical benefits

* The Sparrow’s low profile and guidewire integration allows for significantly improved delivery and access to distal lesions, lesions in tortuous anatomy, small vessels, lesions distal to previously placed stents, and access through stent struts to treat bifurcations.

* The Sparrow allows direct access to the lesion with the Sparrow used as the lead guidewire. The Sparrow guidewire can then be used to rail a rapid exchange catheter over its shaft and the stent. Alternatively the Sparrow and its stent can fit through any standard .014 inch catheter lumen (infusion or balloon).

CardioMind Assets

CardioMind has developed a portfolio of assets critical to the development and manufacture of stent “in a guidewire” systems. These assets fall into a variety of categories, including:

* Patents, Patent Applications and Trademarks

* CE Mark for Sparrow bare metal stent systems

* Custom built equipment for manufacturing stent systems

* Technology and intellectual property related to stent “in a guide wire” systems

* Key know-how and expertise in manufacturing smallest profile stent system approved for sale

* Technology and intellectual property related to drug coating the Sparrow system utilizing a biodegradable polymer

* Patient Data from 2 clinical trials involving 170 patients

The assets of CardioMind will be sold in whole or in part (collectively, the “CardioMind Assets”). The sale of these assets is being conducted with the cooperation of CardioMind. CardioMind and its employees will be available to assist purchasers with due diligence and a prompt, efficient transition to new ownership. Notwithstanding the foregoing, CardioMind should not be contacted directly without the prior consent of Gerbsman Partners.

The Bidding Process for Interested Buyers

Interested and qualified parties will be expected to sign a nondisclosure agreement (attached hereto as Exhibit A) to have access to key members of the management and intellectual capital teams and the due diligence “war room” documentation (the “Due Diligence Access”). Each interested party, as a consequence of the Due Diligence Access granted to it, shall be deemed to acknowledge and represent (i) that it is bound by the bidding procedures described herein; (ii) that it has an opportunity to inspect and examine the CARDIOMIND Assets and to review all pertinent documents and information with respect thereto; (iii) that it is not relying upon any written or oral statements, representations, or warranties of CARDIOMIND, Inc., Gerbsman Partners, or their respective staff, agents, or attorneys; and (iv) all such documents and reports have been provided solely for the convenience of the interested party, and neither CARDIOMIND nor Gerbsman Partners (or their respective, staff, agents, or attorneys) makes any representations as to the accuracy or completeness of the same.

Following an initial round of due diligence, interested parties will be invited to participate with a sealed bid, for the acquisition of the CardioMind Assets. Sealed bids must be submitted so that the bid is actually received by Gerbsman Partners no later than Thursday, June 3 at 3:00 p.m. Pacific Standard Time (the “Bid Deadline”) at CardioMind’ office, located at 257 Humbolt Court Sunnyvale, CA 94089. Please also email Steve@GerbsmanPartners.com with any bid.

Bids should identify those assets being tendered for in a specific and identifiable way. The attached CardioMind fixed asset list may not be complete and Bidders interested in the CardioMind Assets must submit a separate bid for such assets. Be specific as to the assets desired. CardioMind cash and accounts receivable are not being offered for bid as par of the CardioMind Assets.

Any person or other entity making a bid must be prepared to provide independent confirmation that they possess the financial resources to complete the purchase where applicable. All bids must be accompanied by a refundable deposit check in the amount of $200,000 (payable to CardioMind, Inc.). The winning bidder will be notified within 3 business days after the Bid Deadline. Unsuccessful bidders will have their deposit returned to them. CARDIOMIND reserves the right to, in its sole discretion, accept or reject any bid, or withdraw any or all assets from sale.

CARDIOMIND will require the successful bidder to close within 7 business days. Any or all of the assets of CardioMind will be sold on an “as is, where is” basis, with no representation or warranties whatsoever.

All sales, transfer, and recording taxes, stamp taxes, or similar taxes, if any, relating to the sale of the CardioMind Assets shall be the sole responsibility of the successful bidder and shall be paid to CardioMind at the closing of each transaction.

For additional information, please see below:

About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. Since 2001, Gerbsman Partners has been involved in maximizing value for 60 Technology, Life Science and Medical Device companies and their Intellectual Property,, through its proprietary “Date Certain M&A Process” and has restructured/terminated over $790 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.3 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in Boston, New York, Washington, DC, Alexandria, VA, San Francisco, Europe and Israel.

Gerbsman Partners
Phone: +1.415.456.0628, Fax: +1.415.459.2278
Email: Steve@GerbsmanPartners.com

Read Full Post »

Gerbsman Partners has been retained by XTENT, Inc. to solicit interest for the acquisition of all, or substantially all, the assets of XTENT, Inc. (“XTENT”).  The Sale of XTENT’s assets is being conducted pursuant to a Plan of Complete Liquidation and Dissolution which was approved by XTENT’s board of directors on May 11, 2009 and by its stockholders on August 3, 2009 (“Plan of Dissolution”).

The information in this memorandum does not constitute in whole or in part an offer or a contract.

The information contained in this memorandum relating to XTENT’s Assets has been supplied by XTENT. It has not been independently investigated or verified by Gerbsman Partners or its agents.

Potential purchasers should not rely on any information contained in this memorandum or provided by XTENT, or Gerbsman Partners (or their respective staff, agents, and attorneys) in connection herewith, whether transmitted orally or in writing as a statement, opinion, or representation of fact. Interested parties should satisfy themselves through such independent investigations as they or their legal and financial advisors see fit.

XTENT, Gerbsman Partners, and their respective staff, agents, and attorneys, (i) disclaim any and all implied warranties concerning the truth, accuracy, and completeness of any information provided in connection herewith and (ii) do not accept liability for the information, including that contained in this memorandum, whether that liability arises by reasons of XTENT’s or Gerbsman Partners’ negligence or otherwise.

It is expected that any sale of the XTENT Assets will be made on an “as-is,” “where-is,” and “with all faults” basis, without any warranties, representations, or guarantees, either express or implied, of any kind, nature, or type whatsoever from, or on behalf of XTENT or Gerbsman Partners. Without limiting the generality of the foregoing, XTENT and Gerbsman Partners and their respective staff, agents, and attorneys,  hereby expressly disclaim any and all implied warranties concerning the condition of the XTENT Assets and any portions thereof, including, but not limited to, the implied warranties of habitability, merchantability, or fitness for a particular purpose.

This memorandum contains confidential information and is not to be supplied to any person without Gerbsman Partners’ prior consent. This memorandum and the information contained herein are subject to the non-disclosure agreement attached hereto as Exhibit A.

Headquartered in Menlo Park, California, XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent systems for the treatment of cardiovascular artery disease.

XTENT believes its assets are attractive for a number of reasons:

XTENT’s Custom NX® drug eluting stent systems are CE Marked and represent:
– the first customizable stent system ever approved for sale
– the longest coronary stent system ever approved for sale
– the first approved stent system to allow treatment of multiple lesions using one catheter
– the first approved stent system to incorporate a post-dilatation feature into the delivery catheter.

Post dilatation is the use of a balloon to further expand a section of a stent after it has been deployed in order to better position that section of the stent against the blood vessel walls.  Other stent systems require the insertion of a separate balloon in order to post-dilatate.

XTENT’s Custom NX drug eluting stent systems received a conditional IDE (Investigational Device Exemption) from the United States Food and Drug Administration.

XTENT’s Intellectual Property includes 31 issued US patents, 57 pending US patent applications, 11 granted international patents and 99 international pending patent applications related to custom-length stent deployment, stent structure, drug eluting balloons and bioabsorbable medical implants.

Custom NX is a differentiated stent and delivery technology
– The ability to tailor the stent to the lesion is unique to XTENT and may offer significant clinical benefits
– XTENT’s segmented stent design allows for improved deliverability, flexibility and conformability
– Treatment of multiple lesions and balloon post-dilatation with a single catheter
– Treatment of long lesions up to 60mm in 6mm increments without the need to overlap
– Compelling clinical data from 248 patients in the CUSTOM I/II/III and PK trials with long term follow-up
– An existing license agreement with Biosensors for Biolimus A9 (BA-9)
– Reduce the number of SKU’s required to stock the cath lab from approximately 50 per company, down to 3

Large and well established drug eluting stent market
– Existing greater than $4.0 billion and growing worldwide drug-eluting stent market
– Existing reimbursement
– Physician base known for rapid adoption of new technologies that provide improved safety/efficacy and/or greater efficiency

Peripheral Stent: XTENT’s peripheral stent technology is a modular customizable nitinol self expanding stent which consists of a series of stent segments. These segments allow the user to customize the length of stent for the lesion treated by controlling the number of discrete segments to be deployed in situ up to 200+mm.

Bioabsorbable Stent: XTENT’s bioabsorbable stent technology has a unique method involving the integration of thermally controlled nanoparticles into the polymer of the stent. Once activated by light, the nanoparticles temporarily allow the stent to become compliant in order to allow for its expansion.

Drug Eluting Balloon: XTENT’s custom stent IP and technology can be applied to a customizable drug eluting balloon system which may offer significant potential benefits versus fixed length drug eluting balloons.  First, XTENT’s sheath protected delivery system protects the balloon’s drug coating as it is delivered to the target lesion. Second, the ability to customize the length and diameter of the stent while in the patient’s artery may reduce the incidence of geographic miss.

XTENT Company Profile

XTENT was founded in 2002 and completed its initial public offering in 2007 raising net proceeds of $68.2 million.  Prior to its IPO, XTENT raised approximately $75 million through private placements of its convertible preferred stock involving leading venture capital firms including Morgenthaler Ventures, Advanced Technology Ventures and Split Rock Partners.

XTENT is a developer of innovative customizable drug eluting stent systems for the treatment of cardiovascular disease. The XTENT® platforms have been designed for use in the heart to treat coronary artery disease, or CAD, and for use outside the heart to treat peripheral vascular disease, or PVD.  The XTENT Custom NX drug eluting stent, or DES, system is the only stent system designed to offer personalized care to today’s CAD patients, and to benefit those delivering their care by improving efficacy and efficiency while reducing costs.

XTENT’s drug eluting stent systems are the only stent systems designed to enable physicians to customize both the length and diameter of the stent at the site of the diseased section of the artery, or lesion.  In addition, XTENT’s stent systems are designed to treat single, multiple, or long lesions with one device, whereas the current generation of drug eluting stents would require multiple stents, multiple balloons and catheter exchanges.

Impact of Technology on the Market
XTENT believes that its customizable stent technology offers advantages over currently marketed fixed length drug eluting stents.
– The Custom NX is coated with a formulation of BA-9 and PLA. BA-9 is the first drug that was developed specifically for the treatment of cardiovascular disease to receive an Investigational Device Exemption from the FDA.  Additionally, PLA is a bioabsorbable material that the body ultimately absorbs over time as the artery heals.
– Using the Custom NX60 for long lesions avoids the need to overlap multiple shorter stents, potentially eliminating stent fracture and reducing inventory for the manufacturer and cath lab.
– Customizing stent length at the site of the lesion may allow for more accurate placement of stents.
– Custom NX is intended to provide faster procedures for physicians (both planning & execution) due to the ability to treat multiple lesions and perform post-dilatation with a single device and reduced exchanges.
– The average DES procedure uses 1.5 stents at an average cost of $2,000 per stent.  Custom NX offers possible cost savings by treating multiple lesions or long lesions with one device.  Potential additional cost savings may be realized by eliminating the need for a separate post-dilatation balloon.

XTENT’s Assets
XTENT has developed a portfolio of assets critical to the development and manufacture of customizable drug eluting stent systems. These assets fall into a variety of categories, including:

– Patents, Patent Applications and Trademarks
– CE Mark for Custom NX drug eluting stent systems
– Conditional Investigational Device Exemption for Custom NX drug eluting stent systems
– A license for Biolimus A-9 and bioabsorbable PLA coating from Biosensors
– Custom built equipment for manufacturing drug eluting stent systems
– Technology and intellectual property related to custom length peripheral stent systems
– Technology and intellectual property related to bioabsorbable stents
– Patient Data from 4 clinical trials involving 248 patients.

The assets of XTENT will be sold in whole or in part (collectively, the “XTENT Assets”). The sale of these assets is being conducted with the cooperation of XTENT.  XTENT and its employees will be available to assist purchasers with due diligence and a prompt, efficient transition to new ownership. Notwithstanding the foregoing, XTENT should not be contacted directly without the prior consent of Gerbsman Partners.

The Sale of the XTENT Assets is being conducted pursuant to the Plan of Dissolution.  As provided under the Plan of Dissolution, XTENT expects the sale of the XTENT Assets to be completed without any further vote or action by XTENT’s stockholders.

The Bidding Process for Interested Buyers

Interested and qualified parties will be expected to sign a nondisclosure agreement (attached hereto as Exhibit A) to have access to key members of the management and intellectual capital teams and the due diligence “war room” documentation (the “Due Diligence Access”). Each interested party, as a consequence of the Due Diligence Access granted to it, shall be deemed to acknowledge and represent (i) that it is bound by the bidding procedures described herein; (ii) that it has an opportunity to inspect and examine the XTENT Assets and to review all pertinent documents and information with respect thereto; (iii) that it is not relying upon any written or oral statements, representations, or warranties of XTENT, Gerbsman Partners, or their respective staff, agents, or attorneys; and (iv) all such documents and reports have been provided solely for the convenience of the interested party, and neither XTENT nor Gerbsman Partners (or their respective, staff, agents, or attorneys) makes any representations as to the accuracy or completeness of the same.

Following an initial round of due diligence, interested parties will be invited to participate with a sealed bid, for the acquisition of the XTENT Assets. Sealed bids must be submitted so that the bid is actually received by Gerbsman Partners no later than Friday, September 18, 2009 at 3:00 p.m. Pacific Standard Time (the “Bid Deadline”) at XTENT’ office, located at 125 Constitution Drive, Menlo Park, CA 94025. Please also email steve@gerbsmanpartners.com with any bid.

Bids should identify those assets being tendered for in a specific and identifiable way. The attached XTENT fixed asset list, Exhibit B attached, may not be complete and Bidders interested in the XTENT Assets must submit a separate bid for such assets. Be specific as to the assets desired. XTENT’s cash and accounts receivable are not being offered for bid as part of the XTENT Assets.

Any person or other entity making a bid must be prepared to provide independent confirmation that they possess the financial resources to complete the purchase where applicable. All bids must be accompanied by a refundable deposit check in the amount of $200,000 (payable to XTENT, Inc.). The winning bidder will be notified within 3 business days after the Bid Deadline. Unsuccessful bidders will have their deposit returned to them. XTENT reserves the right to, in its sole discretion, accept or reject any bid, or withdraw any or all assets from sale.

XTENT’s board of directors and its stockholders have previously approved a Plan of Complete Liquidation and Dissolution.  As a result, provided that the Bid conforms to the specifications outlined in this letter, the sale of XTENT’s assets will not require any additional approval of, or action by, the stockholders of XTENT.  XTENT will require the successful bidder to close within 7 business days.  Any or all of the assets of XTENT will be sold on an “as is, where is” basis, with no representation or warranties whatsoever.

All sales, transfer, and recording taxes, stamp taxes, or similar taxes, if any, relating to the sale of the XTENT Assets shall be the sole responsibility of the successful bidder and shall be paid to XTENT at the closing of each transaction.

For additional information, please see below and/or contact:

Steven R. Gerbsman
(415) 456-0628
steve@gerbsmanpartners.com

Read Full Post »

Gerbsman Partners has been retained by Emphasys Medical, Inc. to solicit interest for the acquisition of all, or substantially all, Emphasys Medical Inc.’s (“Emphasys”)  assets.

Emphasys Medical Company Profile

Founded in 2000, Emphasys is a private, California-based, revenue stage medical device company. Over the past 8 ½ years, the Emphasys has raised approximately $90mm in equity and debt from leading venture capital firms including ABS Ventures, Advanced Technology Ventures, Morgenthaler Ventures, SplitRock Ventures, OrbiMed Advisors, Morgan Stanley Venture Fund, Cargill Ventures, and Western Technology Investment.

Emphasys is a leader in developing innovative, therapeutic devices to treat advanced heterogeneous emphysema. Emphasys’  Zephyr EBV provides therapy for patients whose lungs are hyperinflated due to emphysematous destruction. By reducing the amount of trapped gas in the hyperinflated regions of the lungs, the devices restore the elastic recoil of the lung, therefore improving overall lung function.

Emphasys Medical’s Assets

Emphasys has developed a portfolio of assets critical to the bronchoscopic treatment of emphysema with endobronchial valves.
These assets fall into a variety of categories, including: Patents, Patent Applications and Trademarks

  • Prospective, Randomized Patient Data Set for Treating Heterogeneous Emphysema
  • Prospective, Registry Patient Data Set for Treating Persistent Air Leaks
  • Bronchoscopic Valve Technology and Product Inventory
  • Manufacturing, Design and Calibration Equipment
  • CE Mark for the Zephyr EBV
  • International Revenue
  • Intellectual Capital and Expertise

The assets of Emphasys will be sold in whole or in part (collectively, the “Emphasys Medical Assets”) on an ” as is, where is basis, with no reps and warrtanties whatsoever” and must close in 7 days.  The sale of these assets is being conducted with the cooperation of Emphasys. Emphasys and its employees will be available to assist purchasers with due diligence and a prompt, efficient transition to new ownership. Notwithstanding the foregoing, Emphasys should not be contacted directly without the prior consent of Gerbsman Partners.

For more information, please contact:

Steven R. Gerbsman

(415) 456-0628

steve@gerbsmanpartners.com

Read Full Post »

emphasys-logoEmphasys Medical Inc., a Redwood City, Calif.-based medical device company focused on emphysema, has retained Gerbsman Partners to find a strategic buyer, according to VentureWire. The company canceled an IPO last spring, and before that had raised around $80 million in VC funding. Shareholders include Advanced Technology Ventures (17.8%), Morgenthaler Ventures (13.8%), St. Paul Venture Capital (11.5%) OrbiMed Advisors (13.7%), ABS Ventures (10%), Morgan Stanley Venture Partners (7.4%), Cargill Ventures (6.1%) and Neww Enterprise Associates. www.emphasysmedical.com

Links: peHUB, Biospace, DOW Jones,

Read Full Post »